This photo provided by SK bioscience Co. on Dec. 12, 2023, shows the Novavax vaccine against the XBB.1.5 variant of COVID-19 being distributed. (Imager courtesy of Yonhap)
SEOUL, Dec. 12 (Korea Bizwire) — SK bioscience Co. said Tuesday it has started supplying Novavax’s updated COVID-19 vaccine to target the XBB.1.5 subvariant in South Korea.
The vaccine, the only non-messenger RNA formulation against COVID-19 in the world, will be available for free at designated hospitals and health centers across the country starting next Monday, according to the company, which imports the Novavax product to South Korea.
Last month, the Ministry of Food and Drug Safety approved emergency use of the vaccine on those aged 12 or above.
The vaccine also earned emergency approval from the U.S. Food and Drug Administration in October and the European Medicines Agency’s official approval last month.
(Yonhap)
